CSIR-Central Drug Research Institute in Lucknow has collaborated with a UP-based pharmaceutical firm to develop an improved drug against heart attack and stroke. Aimed at treating coronary and cerebral ailments, the new drug will be produced with the joint efforts of the institute and Marc Laboratories Pvt. Ltd., which has a presence in 13 states. As of now, permission for phase-1 trials of the drug has been obtained.
Durg to help better regulation of the cardiac system
As a part of the agreement, a synthetic compound S-007-867 will be developed which has the potential of preventing excessive platelet collection and regulating blood coagulation. With the help of this medicine, it would easier to mitigate the possibilities of a heart attack by maintaining a controlled velocity of blood flow. As per the information given in the press release by the organisation, a certain kind of experiment on animals indicated better results and now, phase-1 trials will be initiated.
Further, it has been stated that the drug can also be used to treat COVID-led complications. Amongst patients with high D-Dimer and CRP levels, the drug can help in safeguarding the cardiac system.
Move to benefit state's pharmaceutical sector
On this occasion, Prof. Tapas K. Kundu, Director (CDRI) said "This is a great moment for CSIR-CDRI, the premiere drug development and research institute of the country to license out an in house developed compound for further investigations as part of our commitment of affordable healthcare for all." He added that the new development shall work to the advantage of the pharma sector in Uttar Pradesh besides helping cardiac patients.
Mr. Prem Kishore, Chairman Marc Laboratories said, "Marc's association with CSIR-CDRI will be beneficial to both parties and they will be working hard to take the compound forward so that it sees light of the day soon".